Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Graviton BioScience Announces New Preclinical Data Highlighting the Potential of Selective ROCK2 Inhibition in Multiple Sclerosis at Neuroscience 2026

      Graviton Logo

      News provided by

      Graviton BioScience Corporation

      Nov 16, 2026, 08:30 ET

      Share this article

      Share this article


      • Novel, highly selective ROCK2 inhibitor GV300 demonstrated enhanced brain penetration, improved solubility and oral bioavailability.
      • GV300 ameliorated clinical scores as well as reduced demyelination, inflammation, and biomarkers of neurodegeneration in preclinical models of multiple sclerosis (MS).
      • Mechanistic ex vivo studies indicated that selective ROCK2 inhibition promotes oligodendrocyte-mediated myelination and neurite outgrowth, supporting a differentiated approach to target both inflammation and central nervous system (CNS) repair in MS.
      • Data support continued development of GV300 for progressive MS, an area of significant unmet medical need due to a lack of therapies addressing neurodegeneration and myelin repair.

      NEW YORK, Nov. 16, 2026 /PRNewswire/ -- Graviton BioScience Corporation, a clinical-stage biotechnology company developing a diverse pipeline of therapeutics including highly selective Rho-associated coiled-coil-containing protein kinase 2 (ROCK2) inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, today announced new preclinical data, presented on November 15, demonstrating the potential of highly selective, blood-brain-barrier penetrant ROCK2 inhibitors to simultaneously reduce neuroinflammation and promote central nervous system repair in multiple sclerosis (MS). The research evaluated the ability of Graviton's novel, blood-brain-barrier penetrant, highly selective ROCK2 inhibitor GV300, designed specifically for the treatment of progressive MS, to target both the inflammatory and neurodegenerative components of the disease.

      The findings were presented at the Neuroscience 2026 conference in a presentation entitled, "Selective ROCK2 inhibitors ameliorate murine models of multiple sclerosis and demyelination by harnessing inflammation and restoring homeostasis," by Julien Moretti, Ph.D., Director within Graviton's Translational Medicine group, led by Alexandra Zanin-Zhorov, Ph.D., Senior Vice President at Graviton BioScience. The data suggest that GV300 may address multiple drivers of progressive MS, including chronic neuroinflammation, demyelination, neurodegeneration and impaired remyelination.

      Key Findings

      • Reduced neuroinflammation and demyelination. In the Experimental Autoimmune Encephalomyelitis (EAE) model, therapeutic oral administration of GV300 reduced clinical disease scores and demyelination, lowered spinal cord inflammation and neurodegeneration-associated biomarkers.
      • Remyelination in a non-autoimmune model. In a separate non-autoimmune cuprizone-induced demyelination model, GV300 promoted remyelination, supporting an effect beyond modulation of autoimmune inflammation alone.
      • Direct effects on CNS repair pathways. Mechanistic studies showed that selective ROCK2 inhibition enhanced oligodendrocyte-mediated myelination, increased microglial clearance of myelin debris and promoted neurite outgrowth.
      • Differentiated development profile. GV300 demonstrated potent and highly selective ROCK2 inhibition, improved solubility and oral bioavailability and measurable brain exposure in preclinical studies.

      "These findings suggest that selective ROCK2 inhibition has the potential to address multiple components of MS biology simultaneously," said Julien Moretti, Ph.D. "In our preclinical and ex vivo studies, we observed not only a reduction in disease-associated inflammation, but also direct effects on oligodendrocytes, microglia and neurons that are consistent with remyelination and restoration of CNS homeostasis."

      "This combination may be particularly important in progressive MS, where neurodegeneration and the failure of effective repair become increasingly important drivers of the disease, while neuroinflammation becomes less dominant," added Alexandra Zanin-Zhorov, Ph.D.

      "Patients with progressive multiple sclerosis continue to have limited treatment options, particularly when disease progression occurs independently of relapses," said Samuel D. Waksal, Ph.D., Founder and Chief Executive Officer of Graviton BioScience. "There remains a major need for therapies that go beyond controlling peripheral inflammation and address the mechanisms underlying demyelination, neuronal injury, and progressive disability. These findings provide compelling preclinical evidence that selective, brain-penetrant ROCK2 inhibition, such as GV300, may offer a differentiated approach by going beyond controlling inflammation, while simultaneously targeting cellular pathways involved in myelin repair and neuronal health."

      Presentation Details

      Title: Selective ROCK2 inhibitors ameliorate murine models of multiple sclerosis and demyelination by harnessing inflammation and restoring homeostasis

      Presenter: Julien Moretti, Ph.D., Graviton BioScience

      Conference: Neuroscience 2026

      Date and Time: Sunday, November 15, 2026, 8:00 a.m.–12:00 p.m.

      Session: Translational Studies and Therapeutic Strategies in Multiple Sclerosis

      Location: Walter E. Washington Convention Center, Washington, D.C.

      About GV300 and Progressive Multiple Sclerosis

      Progressive multiple sclerosis is characterized by accumulating neurological disability associated with neuroinflammation, demyelination, neuronal injury and inadequate repair within the central nervous system. Although available therapies can reduce inflammatory disease activity, treatment options remain limited for patients whose disability progresses independently of relapses.

      GV300 is Graviton's highly selective, orally available and brain-penetrant ROCK2 inhibitor developed for progressive MS. ROCK2 regulates pro-inflammatory immune signaling as well as cellular pathways involved in neurological function and repair. In preclinical studies, GV300 demonstrated activity across disease severity, inflammation, demyelination, neurodegeneration-associated biomarkers, remyelination and neurite outgrowth.

      About Graviton BioScience

      Graviton BioScience Corporation is a clinical-stage drug discovery and development company dedicated to engineering and developing best-in-class therapeutics for metabolic, central nervous system, inflammatory, fibrotic and other diseases. Graviton has developed a portfolio of selective ROCK2 inhibitors, among other innovative and novel therapies, for patients with fibrotic, autoimmune, and CNS diseases.

      Leading the Company is Samuel D. Waksal, Ph.D., the founder and former Chairman and Chief Executive Officer of Kadmon Pharmaceuticals, which was acquired by Sanofi. Dr. Waksal is also the founder and former Chief Executive Officer of ImClone Systems, which was acquired by Eli Lilly, and a founder of MeiraGTx.

      Forward-Looking Statements

      This press release contains forward-looking statements, including statements regarding the potential therapeutic benefits of GV300 and selective ROCK2 inhibition, the potential applicability of preclinical findings to multiple sclerosis, including progressive forms of MS, and Graviton BioScience's research and development plans. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The findings described herein are preclinical, and results observed in preclinical models may not be predictive of results in humans. Forward-looking statements speak only as of the date of this press release, and Graviton BioScience undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

      Media Contact

      Graviton BioScience Corporation
      Melanie Glickman
      [email protected]
      1 (332) 318-2019

      SOURCE Graviton BioScience Corporation

      Modal title

      Also from this source

      Graviton BioScience Announces FDA Fast Track Designation for GV101 for the Treatment of Friedreich's Ataxia

      Graviton BioScience Announces FDA Fast Track Designation for GV101 for the Treatment of Friedreich's Ataxia

      Graviton BioScience today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to GV101, the Company's...

      Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

      Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

      Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company, announced the publication of peer-reviewed data from a...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.